每经AI快讯，Wind数据显示，A股2月2日共有3768只个股获融资资金买入，有447股买入金额超亿元。 其中，新易盛、中际旭创、紫金矿业融资买入金额排名前三，分别获买入48.55亿元、45.35亿元、21.78 亿元。 从融资买入额占当日总成交金额比重来看，有2只个股融资买入额占比超30%。其中楚天高速、吉贝 尔、杭电股份融资买入额占成交额比重排名前三，分别为35.31%、34.17%、28.87%。 从融资净买入金额来看，有23只个股获融资净买入超亿元。其中，湖南黄金、中国西电、胜宏科技融资 净买入金额排名前三，分别获净买入8.14亿元、2.82亿元、2.67亿元。 （文章来源：每日经济新闻） ...

证券日报网讯2月2日，吉贝尔在互动平台回答投资者提问时表示，截至2026年1月30日收市，公司股东 总数为7919户。 ...

Core Insights - The article highlights the remarkable industrial development of Zhenjiang, a small city in Jiangsu Province, which has achieved significant technological and manufacturing milestones despite its limited size and population [2][5][12]. Group 1: Economic Performance - Zhenjiang has a GDP of 554 billion yuan in 2024, ranking 57th nationally, surpassing larger cities like Taiyuan and Urumqi [7]. - The city ranks 22nd among Chinese cities in the Global Innovation Index, indicating a high level of technological innovation relative to its economic size [8][11]. Group 2: Manufacturing Strength - Zhenjiang's manufacturing sector is robust, with a reported sales revenue of over 368.4 billion yuan in 2024, growing at a rate of 13.2%, which is above the provincial average [14][21]. - The city is home to significant manufacturing clusters, including high-end equipment and new materials, with several companies recognized as "hidden champions" in their respective fields [19][21]. Group 3: Innovation and Technology - Zhenjiang has been recognized for its innovation capabilities, ranking 41st in the National Innovation City Capability Evaluation Report, which assesses cities based on various innovation metrics [9][11]. - The city has a high number of patents, with 29.71 high-value invention patents per ten thousand people, ranking 4th in Jiangsu Province [21]. Group 4: Strategic Development Approach - Zhenjiang has adopted a focused approach to industrial development, concentrating on emerging sectors such as artificial intelligence, low-altitude economy, and new energy storage [24][29]. - The city leverages its geographical position within the Yangtze River Delta to enhance resource sharing and collaboration with larger cities like Shanghai and Nanjing [28][30].

证券日报网讯1月29日，吉贝尔在互动平台回答投资者提问时表示，公司及管理层关注二级市场股票价 格，高度重视股东利益，专注主营业务发展，提升公司核心竞争力，促进公司高质量发展，持续创造价 值，回报股东，回馈社会。 ...

（文章来源：证券日报） 证券日报网讯 1月22日，吉贝尔在互动平台回答投资者提问时表示，公司将持续专注主营业务发展，通 过产品推广、研发创新、投资布局、股权激励、完善研发技术平台等多种措施，持续促进公司高质量发 展。 ...

证券日报网讯 1月22日，吉贝尔在互动平台回答投资者提问时表示，截至2026年1月20日收市，公司股 东总数为7894户。公司股东情况敬请关注公司披露的定期报告。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes its diverse product range and ongoing research and development efforts to ensure long-term stable growth [1] Product Lifecycle and Pipeline Development - The company has a rich variety of products covering multiple therapeutic areas, with its main product, Likujun tablets, showing promising applications in the oral white blood cell-boosting drug sector [1] - The company is also developing innovative drugs such as the antidepressant JJH201501 and the anti-tumor drug JJH201601, supported by its research technology platforms including compound formulation, deuterated drug, and liposome drug development technologies [1]

Core Viewpoint - The stock of Jibeier has experienced fluctuations, with a recent decline of 2.00% and a total market value of 5.863 billion yuan, reflecting mixed investor sentiment and trading activity [1]. Group 1: Stock Performance - As of January 15, Jibeier's stock price is 29.40 yuan per share, with a trading volume of 39.944 million yuan and a turnover rate of 0.67% [1]. - Year-to-date, the stock has decreased by 1.51%, with a 3.29% drop over the last five trading days, a 4.11% increase over the last 20 days, and a 9.48% decline over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million yuan, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million yuan, up by 12.80% [2]. Group 3: Shareholder Information - As of January 9, 2025, Jibeier has 7,406 shareholders, an increase of 3.35% from the previous period, with an average of 26,928 circulating shares per shareholder, a decrease of 3.24% [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million yuan in dividends, with 252 million yuan distributed over the last three years [3]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed A (011201) and GF Healthcare Stock A (004851), holding 1.2392 million shares and 959,000 shares respectively [3].

Group 1 - The core point of the article is that as of January 9, 2026, the total number of shareholders for the company is 7,406 [1]

Core Viewpoint - Shanghai Gaochong Technology Development Co., Ltd. has been established with a registered capital of 10 million RMB, fully owned by Jiangsu Jibeier Pharmaceutical Co., Ltd. [1] Group 1: Company Information - The legal representative of Shanghai Gaochong Technology Development Co., Ltd. is Liu Binghai [1] - The company is classified as a limited liability company with a business scope that includes technology services, development, consulting, and sales of specialized chemical products [1] - The registered address of the company is located at 668 Shangda Road, Building 1, 5th Floor, Area B, Baoshan District, Shanghai [1] Group 2: Shareholding Structure - Jiangsu Jibeier Pharmaceutical Co., Ltd. holds 100% of the shares in Shanghai Gaochong Technology Development Co., Ltd. [1] Group 3: Business Operations - The business operations include medical research and experimental development, marketing planning, conference and exhibition services, ticketing agency services, business secretary services, and technology intermediary services [1] - The company is authorized to conduct business activities independently based on its business license, except for projects that require approval by law [1] Group 4: Registration and Duration - The business registration is valid until January 8, 2026, with no fixed term thereafter [1] - The registration authority is the Baoshan District Market Supervision Administration [1]